Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Feeling better today ...

<< Previous

Bullboard Posts

Next >>

Comment by bringon10baggeron Jan 12, 2021 3:33pm

142 Views

Post# 32278205

RE:Feeling better today ...

At this stage I would believe Dan would not show all the cards in his hand, create the curiosity lure them to the table and then knocks their socks off..........$$$$$

MrMugsy wrote: It was bothering me that the expected update pre-JPMorgan wasn't as "comprehensive" as I hoped. But after a good night's rest and a little reflection, it's making more sense to me.

We know that January 20th is heavy on the minds of the ATE Board. It's heavy on the minds of most Boards.

If you are trying to get traction and build your name among institutional investors, the events of January 6th further lead you to believe in market volatility heading into Inauguration Day. There will be limited momentum building at this time. So, slow and steady with all eyes to the end of January.

As the J.P.Morgan ends, yes the company will likely continue with discussions but there could be a pause for a week or so ... as everyone's attention is elsewhere. I'm sure that played on what they want to say pre-Inauguration and what they plan to do post-Inauguration.

Just thinking out loud.